Bladder Cancer Weekly

February 22, 2021

Videos

Peer-to-Peer Clinical Conversations

Circulating Tumor DNA - Guiding Treatment Decisions in Bladder Cancer - Lars Dyrskjøt

Lars Dyrskjøt

In this conversation with Ashish Kamat, Lars Dyrskjøt, an expert in the field of molecular markers and personalized medicine speaks about circulating tumor DNA and the potential as a tumor for guiding treatment decisions in bladder cancer.

View

Advances from 2020 in the Management of Muscle Invasive Non-Metastatic Bladder Cancer - Bernard Bochner

Bernard Bochner

Bernard Bochner joins Ashish Kamat in this discussion discussing the advancements throughout 2020 in muscle-invasive non-metastatic bladder cancer.

View

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

The validity, reliability, and reviewer acceptance of VI-RADS in assessing muscle invasion by bladder cancer: a multicenter prospective study.

Variation in Lymph Node Yield After Radical Cystectomy.

A Systematic Review of the Efficacy and Safety of Outpatient Bladder Tumour Ablation.

Gender differences in trends of bladder cancer mortality-to-incidence ratios according to health expenditure in 55 countries.

Achieving disease free distal ureteral margin at the time of radical cystectomy: Why and for whom? (an overview of literature).

Locoregional recurrence after cystectomy in muscle invasive bladder cancer: Implications for adjuvant radiotherapy.

Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB.

Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study.

A Systematic Review and Scoping Analysis of Smoking Cessation after a Urologic Cancer Diagnosis.

Staging 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Changes Treatment Recommendation in Invasive Bladder Cancer.

Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer.

Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes.

Hexylaminolevulinate-mediated fluorescent urine cytology with a novel automated detection technology for screening and surveillance of bladder cancer.

Fluorescent cystoscopy-assisted en bloc transurethral resection versus conventional transurethral resection in patients with non-muscle invasive bladder cancer: study protocol of a prospective, open-label, randomized control trial (the FLEBER study).

EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, Inc.
548 Market Street #41552
San Francisco, CA 94104-5401

You are receiving this email because you have chosen to receive emails from UroToday.

Bladder Cancer Weekly

Bladder Cancer

Login